$USNA

USNA vs. STVN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences ( USNA Quick QuoteUSNA - ) and Stevanato Group ( STVN Quick QuoteSTVN - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Sep 15, 2025, 3:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 16, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
USNA vs. STVN: Which Stock Is the Better Value Option? — source image
Decision brief

The 30-second read

$USNABullishMed
01

Why it matters

The bullish sentiment towards USNA suggests increased investor interest, potentially leading to short-term price appreciation.

02

Market read

The focus on USNA indicates a favorable outlook for its stock among value investors, with sector-wide implications for health sciences stocks.

03

What to watch

Potential regulatory changes or earnings reports could influence USNA's stock performance unexpectedly.

Timing: Immediate to short-term

Background

The article compares USNA and STVN to identify the more attractive value stock within the Medical - Drugs sector.

Company-level read

Ticker impact

$USNABullishMedium confidence
Context

High relevance due to bullish sentiment and industry significance.

Expected impact

Moderate increase in stock price over the next 1-3 months.

Evidence & confidence

Recent positive sentiment and industry relevance support upward movement, but lack of current technical data limits certainty.

$STVNNeutralLow confidence
Context

Low relevance due to minimal sentiment impact and industry overlap.

Expected impact

Limited or no significant price change expected.

Evidence & confidence

Low relevance score and neutral sentiment indicate minimal trading impact.

Market effects

Positive outlook for the Medical - Drugs sector, potentially benefiting related stocks.

Limited regional impact; primarily US-focused.

Moderate, as USNA operates globally and may influence sector sentiment.

Counterpoint

The positive sentiment may be overextended; a correction could occur if broader market conditions deteriorate.

Key entities

  • USANA Health Sciences

    A global health and wellness company specializing in nutritional and personal care products.

  • Stevanato Group

    A provider of drug containment and delivery systems.

Related articles

$USNAMedAI 8/10

USANA (USNA) Q2 2026 Earnings Call Transcript

USANA (USNA) held its Q2 2026 earnings call. Management said Core Nutritional was stable, with Mainland China showing renewed strength. The company recorded a preliminary $29 million noncash goodwill impairment and $9 million income tax expense on a $19 million pretax loss. USANA ended the quarter with $169 million cash, zero debt, and $20 million free cash flow, and lowered its fiscal 2026 outlook due to HYA DTC marketing and Rise net sales.

$USNAMedAI 8/10

USANA Health Sciences Q2 Earnings Call Highlights

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.

$USNAHighAI 9/10

Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.